Rayaldee is an administration of 25-hydroxyvitamin d3 owned by Eirgen and released on 17 June, 2016. Available in capsule, extended release; oral dosage forms, this drug has a total of 16 patents, none of which have expired. The generic version of Rayaldee is likely to be released after 14 March, 2034.
The generic version of Rayaldee is expected to be available after 14 March, 2034, as the last patent expires on this date. The total of 16 drug patents of Rayaldee includes patents that protect it well into the 2030's, ensuring no generics will be available for the drug until then.
Rayaldee, with its active ingredient calcifediol, is used for the treatment of secondary hyperparathyroidism with sustained release 25-hydroxyvitamin d in chronic kidney disease patients receiving various other treatments. It maintains serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d, and reduces the patient's serum parathyroid hormone level over at least 10 hours. The drug is also used for treating patients having 25-hydroxyvitamin d insufficiency or deficiency.
Rayaldee holds 16 patents with none expired. The major patents related to Rayaldee protect it until 14 March, 2034, after which the release of Rayaldee generic is possible. Below are the details of the patent: